Reva Medical’s Fantom bioresorbable, drug-eluting vascular scaffold succeeds at 6 months

As some companies have worked to improve drug-eluting stents by making them bioresorbable, some voices in the coronary intervention space have expressed concern over the rates of late stent thrombosis and repeat percutaneous coronary intervention seen with the devices.

In a study published in the September issue of JACC: Cardiovascular Intervention, Reva Medical‘s (ASX:RVA) Fantom coronary bioresorbable vascular scaffold succeeded after six months. The device was designed to address challenges like strut size and expansion capacity, the researchers wrote.

Get the full story at our sister site, Drug Delivery Business News.

The post Reva Medical’s Fantom bioresorbable, drug-eluting vascular scaffold succeeds at 6 months appeared first on MassDevice.

from MassDevice http://ift.tt/2jLCp9g